GlaxoSmithKline

COVID-19 accelerated mRNA vaccine development, leading to record profits and FDA approval of mRNA vaccines. Moderna and Pfizer/BioNTech are expanding their mRNA pipelines into other diseases, with Moderna's RSV vaccine recently approved. The mRNA therapeutics market is projected to reach $68 billion by 2030. mRNA technology is favored for its rapid development potential compared to traditional vaccines. Five mRNA vaccine candidates, including Pfizer/BioNTech's influenza vaccine and Moderna's combination COVID-19/influenza vaccine, are highlighted as near-future prospects.

AstraZeneca's Imfinzi in bladder cancer reduced death risk by 25%; Merck and Eisai's combo in liver cancer cut progression or death risk by a third; Bristol's lung cancer approach faced criticism for 'cherry-picking' subgroups.

GSK and iTeos' anti-TIGIT antibody belrestotug, combined with GSK's PD-1 inhibitor Jemperli, showed higher objective response rates in PD-L1-positive NSCLC patients in the GALAXIES Lung-02 study, though with higher discontinuation rates and treatment-related deaths. The 400mg dose is moving to phase 3 trials.

The United States RNA Polymerase Inhibitor Market is projected to reach USD xx.x billion by 2031, driven by advancements in clinical diagnostics and precision medicine. Key players include Johnson & Johnson, AstraZeneca, and Pfizer. Market segments include types like Veliparib and applications in hospital, retail, and online pharmacies. Regional analysis highlights North America's dominance, Europe's strategic alliances, and Asia-Pacific's growing energy demand.

Pembrolizumab plus chemoradiotherapy significantly improved OS for women with high-risk locally advanced cervical cancer, making it the new standard of care.

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.

The article discusses the importance of SSR (Server-Side Rendering) in modern web development, emphasizing its role in enhancing performance and user experience. It highlights the use of SSR-service-entry.770d26512fc8d957974b.js as a key component in implementing SSR.

Bicara Therapeutics raised $315 million in IPO to fund a pivotal study for its head and neck cancer therapy, ficerafusp alfa, which targets EGFR and TGF-beta signaling. The drug, combined with Keytruda, showed a 54% overall response rate in advanced HNSCC patients, with 64% in HPV-negative cases. A Phase 2/3 trial is planned for 2025.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

European stock markets closed higher; Stoxx Europe 600 gained 0.72%, Swiss Market Index rose 0.46%, France's CAC increased 0.41%, FTSE up 0.39%, and Germany's DAX closed 0.92% higher. Eurostat reported a 0.3% decline in euro area industrial production and a 2.6% job vacancy rate in Q2. France's consumer price index rose 0.5% in August. HSBC discusses selling its South African unit, Grifols seeks consultancy for minority investors, GSK's Blenrep gets breakthrough therapy designation in China, and Ascendis Pharma reports clinical activity in ovarian cancer trial.